Published March 5, 2022
| Version v1
Journal article
Patient-Reported Outcomes in the Acute Phase of the Randomized Hypofractionated Irradiation for Prostate Cancer (HYPRO) Trial
- 1. Rwanda Cancer Centre, Rwanda Military Hospital, Kigali (Rwanda)
- 2. Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam (Netherlands)
- 3. Department of Radiotherapy, Erasmus MC Cancer Institute, Rotterdam (Netherlands)
Description
Many patients experience bowel and bladder toxicity during the acute phase of radiation therapy for prostate cancer. Recent literature indicates that hypofractionation (HF) might increase this acute response but little is known on patient-reported outcome during this phase with HF. We evaluated the course of patient-reported acute symptoms during HF versus standard fractionated (SF) radiation therapy within the hypofractionated irradiation for prostate cancer (HYPRO) trial.
Availability note (English)
Available from http://dx.doi.org/10.1016/j.ijrobp.2021.10.139Additional details
Identifiers
- DOI
- 10.1016/j.ijrobp.2021.10.139;
- PII
- S0360301621030492;
Publishing Information
- Journal Title
- International Journal of Radiation Oncology, Biology and Physics
- Journal Volume
- 112
- Journal Issue
- 4
- Journal Page Range
- vp.
- ISSN
- 0360-3016
- CODEN
- IOBPD3
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 53122265
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- BLADDER; FRACTIONATED IRRADIATION; HYDROFLUORIC ACID; NEOPLASMS; PATIENTS; PROSTATE; RADIOTHERAPY; SYMPTOMS; TOXICITY
- Descriptors DEC
- BODY; DISEASES; FLUORINE COMPOUNDS; GLANDS; HALOGEN COMPOUNDS; HYDROGEN COMPOUNDS; INORGANIC ACIDS; INORGANIC COMPOUNDS; IRRADIATION; MALE GENITALS; MEDICINE; NUCLEAR MEDICINE; ORGANS; RADIOLOGY; THERAPY; URINARY TRACT
Optional Information
- Copyright
- Copyright (c) 2021 Elsevier Inc. All rights reserved.